New drug combo aims to outsmart tough colorectal cancer
NCT ID NCT06634875
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a new drug called isunakinra to the immunotherapy pembrolizumab can help treat advanced colorectal cancer that has not responded to other treatments. The trial will enroll 20 people with a specific type of tumor (MSS, TMB-H, KRAS-mutated). Researchers will check safety and how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
isunakinra (a drug that blocks IL-1) combined with pembrolizumab (an immunotherapy)
What this could lead to
If it works, this could offer a new treatment option for people with advanced colorectal cancer that has not responded to standard therapies.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hoag Memorial Hospital Presbyterian
RECRUITINGNewport Beach, California, 92658, United States
-
USC/Norris Cancer Center
RECRUITINGLos Angeles, California, 90089, United States
Contact Email: •••••@•••••